[HTML][HTML] Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or …
F Rivera, M Karthaus, JR Hecht, I Sevilla… - International journal of …, 2017 - Springer
Purpose To report planned final overall (OS) and progression-free survival (PFS) analyses
from the phase II PEAK trial (NCT00819780). Methods Patients with previously untreated …
from the phase II PEAK trial (NCT00819780). Methods Patients with previously untreated …
[引用][C] Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or …
F Rivera, M Karthaus, JR Hecht, I Sevilla… - International Journal of …, 2017 - cir.nii.ac.jp
Final analysis of the randomised PEAK trial: overall survival and tumour responses during
first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with …
first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with …
Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or …
F Rivera, M Karthaus, J Hecht, I Sevilla… - International …, 2017 - search.ebscohost.com
Purpose: To report planned final overall (OS) and progression-free survival (PFS) analyses
from the phase II PEAK trial (NCT00819780). Methods: Patients with previously untreated …
from the phase II PEAK trial (NCT00819780). Methods: Patients with previously untreated …
Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or …
F Rivera, M Karthaus, JR Hecht… - International …, 2017 - search.proquest.com
Purpose To report planned final overall (OS) and progression-free survival (PFS) analyses
from the phase II PEAK trial (NCT00819780). Methods Patients with previously untreated …
from the phase II PEAK trial (NCT00819780). Methods Patients with previously untreated …
[HTML][HTML] Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or …
F Rivera, M Karthaus, JR Hecht, I Sevilla… - … Journal of Colorectal …, 2017 - ncbi.nlm.nih.gov
Final analysis of the randomised PEAK trial: overall survival and tumour responses during
first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with …
first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with …
Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or …
F Rivera, M Karthaus, JR Hecht… - International …, 2017 - pubmed.ncbi.nlm.nih.gov
Purpose To report planned final overall (OS) and progression-free survival (PFS) analyses
from the phase II PEAK trial (NCT00819780). Methods Patients with previously untreated …
from the phase II PEAK trial (NCT00819780). Methods Patients with previously untreated …
Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or …
F Rivera, M Karthaus, JR Hecht, I Sevilla… - … Journal of Colorectal …, 2017 - europepmc.org
Purpose To report planned final overall (OS) and progression-free survival (PFS) analyses
from the phase II PEAK trial (NCT00819780). Methods Patients with previously untreated …
from the phase II PEAK trial (NCT00819780). Methods Patients with previously untreated …